Literature DB >> 8131639

In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B.

H Dermoumi1.   

Abstract

The in vitro activity of itraconazole, fluconazole and amphotericin B was tested against 207 yeast strains and 3 Aspergillus fumigatus strains isolated from blood. The other 42 A. fumigatus strains were selected from respiratory tract infections. A microdilution method was employed to determine the inhibitory concentrations to restrain 70% of isolate growth (IC30). The inhibition concentrations of amphotericin B are all around the value 0.25 mg/l with a deviation of two concentration degrees, indicating sensitivity of all strains. The test results of itraconazole showed the majority of strains in the range of sensitivity (200 isolates) and low sensitivity (44 isolates). Five of 19 Candida glabrata strains demonstrated resistance to itraconazole. The results of fluconazole showed a good sensibility of C. albicans, but 4.5% of strains were resistant. Low sensitivity (1 strain) and resistance (24 strains) were evaluated for C. glabrata and C. krusei isolates. No strain of A. fumigatus was inhibited by fluconazole. The data show the necessity of in vitro tests.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8131639     DOI: 10.1159/000239178

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  12 in total

1.  The spheroplast lysis assay for yeast in microtiter plate format.

Authors:  R Ovalle; M Spencer; M Thiwanont; P N Lipke
Journal:  Appl Environ Microbiol       Date:  1999-08       Impact factor: 4.792

2.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

4.  Synergy of nitric oxide and azoles against Candida species in vitro.

Authors:  G E McElhaney-Feser; R E Raulli; R L Cihlar
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 5.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

6.  Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

Authors:  B Jahn; E Martin; A Stueben; S Bhakdi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar blue tests.

Authors:  B Jahn; A Stüben; S Bhakdi
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

8.  Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.

Authors:  F C Odds; L Vranckx; F Woestenborghs
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro.

Authors:  E M Scott; V N Tariq; R M McCrory
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 10.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.